Pular para o conteúdo
Shigelose
ORPHA:810CID-10 · A03.8CID-11 · 1A02DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Sangue / imuneInício todas idadesHerança Unknown
Também conhecida comoShigueloseDisenteria bacilarDisenteria bacteriana

A shigelose é uma infecção bacteriana que causa disenteria, provocada pela bactéria Shigella. Estas são pequenas bactérias Gram-negativas, muito comuns e que pertencem à família das enterobactérias. Existem quatro espécies: S. dysenteriae, S. flexneri, S. boydii e S. sonnei. Todas elas causam disenteria bacilar e afetam exclusivamente seres humanos.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A shigelose é uma infecção intestinal causada por bactérias chamadas *Shigella*, conhecida também como disenteria bacilar. Ela costuma provocar febre, dores fortes no abdômen em forma de cólica e diarreia com muco ou sangue visível. A doença pode atingir pessoas de qualquer idade e requer atenção rápida para evitar desidratação e perda importante de líquidos. No Brasil, a condição é atendida pelas unidades do SUS, embora não conste na lista oficial de diretrizes de doenças raras do Ministério da Saúde.

📋
Informacoes curadas por IA — podem conter imprecisoes

A shigelose é uma infecção bacteriana que causa disenteria, provocada pela bactéria Shigella. Estas são pequenas bactérias Gram-negativas, muito comuns e que pertencem à família das enterobactérias. Existem quatro espécies: S. dysenteriae, S. flexneri, S. boydii e S. sonnei. Todas elas causam disenteria bacilar e afetam exclusivamente seres humanos.

Pesquisas ativas
9 ensaios
61 total registrados no ClinicalTrials.gov
Publicações científicas
2.744 artigos
Último publicado: 2026 Apr 9

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: A03.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
8 sintomas
🩸
Sangue
6 sintomas
📏
Crescimento
3 sintomas
🧠
Neurológico
2 sintomas
💪
Músculos
2 sintomas
👁️
Olhos
2 sintomas

+ 19 sintomas em outras categorias

Características mais comuns

90%prev.
Diarreia mucoide sanguinolenta
Muito frequente (99-80%)
90%prev.
Cãibras abdominais
Muito frequente (99-80%)
90%prev.
Febre
Muito frequente (99-80%)
90%prev.
Dor abdominal
Muito frequente (99-80%)
55%prev.
Leucocitose
Frequente (79-30%)
55%prev.
Fadiga
Frequente (79-30%)
46sintomas
Muito frequente (4)
Frequente (9)
Ocasional (11)
Muito raro (22)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 46 características clínicas mais associadas, ordenadas por frequência.

Diarreia mucoide sanguinolentaBloody mucoid diarrhea
Muito frequente (99-80%)90%
Cãibras abdominaisAbdominal cramps
Muito frequente (99-80%)90%
FebreFever
Muito frequente (99-80%)90%
Dor abdominalAbdominal pain
Muito frequente (99-80%)90%
LeucocitoseLeukocytosis
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico2.744PubMed
Últimos 10 anos200publicações
Pico202586 papers
Linha do tempo
2026Hoje · 2026🧪 1999Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado1
3Fase 35
2Fase 223
1Fase 125
·Pré-clínico7
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 61 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Shigelose

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 6 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

5 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

61 ensaios clínicos encontrados, 9 ativos.

Distribuição por fase
NCT07666750 · Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy…Em breve
PHASE1, PHASE2
NCT06838195 · Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjuga…Ativo
PHASE3Bangladesh
NCT05182749 · Safety and Efficacy of the Bacteriophage Preparation, ShigAc…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT06047821 · Enterics for Global Health (EFGH)Ativo
Bangladesh · Kenya · Malawi +4
NCT06523231 · Study to Expand Safety and Immunogenicity Data With Shigella…Concluído
PHASE2Kenya
NCT06663436 · A Study on the Immune Response and Safety of a Multicomponen…Concluído
PHASE2Kenya
NCT06615375 · A Human Challenge Study to Assess Protection of a Shigella T…Concluído
PHASE2🇺🇸 Estados Unidos
NCT05987488 · ShigETEC Vaccine Study in BangladeshConcluído
PHASE1Bangladesh
NCT04242264 · Phase 2 Shigella Vaccine and ChallengeConcluído
PHASE2🇺🇸 Estados Unidos
NCT04634513 · Shigella CVD 31000: Study of Responses With Shigella-ETEC Va…Concluído
PHASE1🇺🇸 Estados Unidos
NCT05121974 · Tebipenem Trial in Children With ShigellosisConcluído
PHASE2Bangladesh
NCT04992520 · Controlled Human Infection Model Challenge/RechallengeConcluído
PHASE1🇺🇸 Estados Unidos
NCT05073003 · A Study on the Safety and Immune Responses to the GVGH altSo…Concluído
PHASE1, PHASE2🇧🇪 Bélgica · Kenya
NCT04602975 · A Study to Investigate the Safety and Immunogenicity of the …Concluído
PHASE2Kenya
NCT05409196 · Phase 1 Trial for Safety, Tolerability, and Immunogenicity o…Concluído
PHASE1Hungary
NCT04312906 · A Baseline Study in Support of Clinical Evaluation of an Ora…Concluído
Burkina Faso · Zambia
NCT04078022 · Shigella CVD 30000: Study of Responses to Vaccination With S…Concluído
PHASE2🇺🇸 Estados Unidos
NCT03854929 · Ciprofloxacin Versus Azithromycin for Children Hospitalised …Concluído
PHASE4Vietnam
NCT04056117 · A Study to Determine If a New Shigella Vaccine is Safe, Indu…Concluído
PHASE1, PHASE2Kenya
NCT03869333 · Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]Concluído
PHASE1🇺🇸 Estados Unidos
NCT04865497 · Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent …Concluído
PHASE2🇨🇳 China
NCT03527173 · A Study to Evaluate the Efficacy, Safety and Immunogenicity …Concluído
PHASE2🇺🇸 Estados Unidos
NCT03561181 · Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vac…Concluído
PHASE1🇨🇳 China
NCT03089879 · A Study to Evaluate Safety and Immunogenicity of 1 Booster D…Concluído
PHASE1🇫🇷 França
NCT02934178 · Shigella WRSS1 Vaccine Trial in BangladeshConcluído
PHASE1Bangladesh
NCT02816346 · Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challe…Concluído
PHASE1🇺🇸 Estados Unidos
NCT02797236 · SF2a-TT15 Conjugate Vaccine in Healthy Adult VolunteersConcluído
PHASE1🇮🇱 Israel
NCT02531685 · Phase 1 Study of dmLT ID Vaccination in Healthy AdultsConcluído
PHASE1🇺🇸 Estados Unidos
NCT02646371 · Phase 2b Challenge Study With the Bioconjugate Vaccine Flexy…Concluído
PHASE2🇺🇸 Estados Unidos
NCT02445963 · Safety and Immunogenicity of Artificial Invaplex (Shigella F…Concluído
PHASE1🇺🇸 Estados Unidos
NCT02388009 · Safety and Tolerability of a Bioconjugate Vaccine Against Sh…Concluído
PHASE1🇺🇸 Estados Unidos
NCT02105714 · Diagnosis of Neglected Tropical Diseases Among Patients With…Concluído
Côte d’Ivoire · Indonesia · Mali +1
NCT02034500 · Evaluate a New Shigella Sonnei Vaccine Administered Either b…Concluído
PHASE1🇬🇧 Reino Unido
NCT02017899 · A Phase 1, Dose Escalation Study, to Evaluate a New Shigella…Concluído
PHASE1🇫🇷 França
NCT01813071 · Safety Study of Live Attenuated Oral Shigella (WRSS1) Vaccin…Concluído
NABangladesh
NCT01336699 · Safety and Immunogenicity of Two Live, Attenuated Oral Shige…Concluído
PHASE1🇺🇸 Estados Unidos
NCT01531530 · Safety and Efficacy Study of CVD 1208S, a Live, Attenuated O…Concluído
PHASE1🇺🇸 Estados Unidos
NCT01369927 · Shigella Sonnel O-SPC/rBRU Conjugate VaccineConcluído
PHASE1🇮🇱 Israel
NCT01509846 · Safety Study of Inactivated Shigella Whole Cell Vaccine in A…Concluído
PHASE1🇺🇸 Estados Unidos
NCT01080716 · Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccin…Concluído
PHASE1, PHASE2Thailand
NCT01069471 · Safety and Reactogenicity of Bioconjugate Vaccine to Prevent…Concluído
PHASE1🇨🇭 Suíça
NCT00485134 · Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and As…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00742469 · Rifaximin for Prevention of Travellers' DiarrheaConcluído
PHASE3🇲🇽 México
NCT00210288 · Healthy Adult Volunteer Study for Two Doses of a Shigella Va…Concluído
PHASE2🇫🇷 França · 🇬🇧 Reino Unido
NCT00800930 · Therapeutic Induction of Endogenous AntibioticsConcluído
PHASE2Bangladesh
NCT00082069 · Invaplex 50 Vaccine Dose-RangingConcluído
PHASE1🇺🇸 Estados Unidos
NCT00368316 · Safety, Immunogenicity and Efficacy of Shigella Conjugate Va…Concluído
PHASE3🇮🇱 Israel
NCT00321126 · Zinc Supplementation in Shigella PatientsConcluído
PHASE3
NCT05156528 · Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonn…UNKNOWN
PHASE3🇨🇳 China
NCT04694235 · Egg Intervention During Pregnancy in IndonesiaUNKNOWN
NAIndonesia
NCT03778125 · Multidrug Resistant Shigella Infection in BangladeshUNKNOWN
Bangladesh
NCT01612572 · A Registry Study on Xiyanping(a Chinese Medicine Injection) …UNKNOWN
NCT00866476 · Safety and Efficacy Study of CVD 1208S, a Live, Attenuated O…Encerrado
PHASE2🇺🇸 Estados Unidos
NCT00866242 · Safety and Efficacy Challenge Study of CVD 1208S, a Live, At…Encerrado
PHASE2🇺🇸 Estados Unidos
NCT03038243 · Safety, Immunogenicity and Efficacy Study of Inactivated Who…Cancelado
PHASE2🇺🇸 Estados Unidos
NCT01399424 · Shigella Sonnei OSPC-rDT Conjugate VaccineCancelado
PHASE1
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
870 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 870

#1

Shigella flexneri and Shigella sonnei among children under five in Kenya's urban informal settlement.

Gut pathogens2026 Mar 22

Shigella species are a significant global public health threat with the highest burden of Shigella-associated diarrhoea in children under five years of age, particularly in low- and middle-income countries. Given the high burden of shigellosis in these settings, there is a need for continuous surveillance to identify the prevalent species, risk factors, and determine appropriate intervention strategies. This study aimed to determine the prevalence of Shigella flexneri (S. flexneri) and Shigella sonnei (S. sonnei), assess risk factors and identify Antimicrobial Resistance (AMR) genes present in samples positive for either species among children under five in Mukuru informal settlement. Between August 2023 and November 2024, 386 children presenting with diarrhoea at any of the four selected health facilities in Mukuru were enrolled. Stool samples or rectal swabs were collected and subjected to TaqMan Polymerase Chain Reaction (TAC PCR) for the detection of S. flexneri, S. sonnei and selected AMR genes. Case Report Forms (CRF) and structured questionnaires were used to collect medical history, behavioural and socioeconomic data, respectively. The prevalence of S. flexneri and S. sonnei among the 386 participants was 15.54% (60/386). Positivity for S. flexneri and S. sonnei by age group was highest among children aged 12-23 months (24.84%, 40/161) and lowest among those aged 24-59 months (2.08%, 2/96). S. flexneri was the most prevalent species, with serotypes 2 and X being the most detected. Among the samples positive for S. flexneri and S. sonnei, the mphA gene was detected in 98.33% (59/60), the β-lactamase gene CTX-M1-9 was present in 85% (51/60), and CTX-M2-8-25 was identified in 26.67% (16/60) of samples. Age (aOR = 1.025, 95% CI: 1.003-1.047, P = 0.027) and obtaining vegetables from the market (aOR = 2.737, 95% CI: 1.081-6.930, P = 0.034) were significantly associated with shigellosis. These findings show that shigellosis due to S. flexneri and S. sonnei remains a significant contributor to the burden of diarrheal disease, particularly among young children. The high prevalence of AMR genes, especially mphA and CTX-M β-lactamases, indicates widespread resistance to macrolides and extended-spectrum β-lactams. Addressing this challenge may require a multifaceted approach, including enhanced antimicrobial resistance surveillance, strengthened Water, Sanitation, and Hygiene (WASH) interventions, and the potential deployment of Shigella vaccines among vulnerable populations.

#2

Shigella flexneri 1c bacteremia in a child: a case report.

Gut pathogens2026 Feb 14

Shigellosis is a significant public health issue in developing countries, particularly affecting young children under the age of five. While it primarily causes gastrointestinal infections, there are rare complications, such as bacteremia, that mainly occur in young children. We present a case of dysentery caused by Shigella flexneri serotype 1c, followed by bacteremia. A 13-month-old Afghan child presented with fever, dysentery, distended abdomen, mild tenderness, and dehydration. He did not respond to empirical treatment with ceftriaxone. However, he was successfully treated with a combination of gentamicin and ciprofloxacin. This is the first report of a patient in Iran who was positive for S. flexneri serotype 1c and harbored the ipaB, ipaC, ipaD, ipaH, ipgD, virA, and sen virulence factors. This case alerts clinicians to consider the possibility of Shigella bacteremia in young children. Early and accurate diagnosis can improve management and prognosis to reduce the risk of fatality outcomes. Additionally, it emphasizes the need to characterize the role of Shigella spp. virulence genes in causing bacteremia.

#3

Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis.

Clinical and translational science2026 Jan

Increasing antimicrobial resistance poses a serious challenge for the treatment of Shigella infections, and there is an urgent need for alternative antibacterial treatments. We conducted a clinical trial to investigate the efficacy of oral tebipenem pivoxil, compared to intravenous ceftriaxone, in Bangladeshi children with shigellosis. Using demographic data of 2249 Bangladeshi children with suspected shigellosis, population pharmacokinetic (PK) simulations were conducted to simulate tebipenem PK profiles in children with the proposed dosing regimen. Subsequently, the model predictions estimated each virtual participant's fraction of time over the 3-day treatment period during which simulated free tebipenem plasma concentration was above the minimum inhibitory concentration (fT > MIC). Variability associated with the prevalence of different Shigella species in Bangladeshi children and the MIC distributions were incorporated. Shigella treatment effect was assumed for participants that had fT > MIC for at least 40% of the 3-day treatment period (40% fT > MIC). The probability of achieving 40% fT > MIC was 86.4% for 4 mg/kg tebipenem pivoxil three times daily (TID) dosing and 92.4% with 3 mg/kg tebipenem pivoxil four times daily (QID) dosing. Lastly, the probability of tebipenem pivoxil being non-inferior to ceftriaxone, in a clinical trial containing 66 participants per arm, was evaluated for two dosing regimens. Three levels of ceftriaxone resistance were simulated to examine how dynamic ceftriaxone resistance may impact the trial outcome. Our findings suggest that more frequent tebipenem pivoxil dosing may increase the chance of producing treatment effects, contribute valuable insights to inform dosing strategy selection, and demonstrate a workflow that can be adapted to other drugs and diseases.

#4

Shigellosis: antibiotics should be strictly reserved for severe disease and cases at very high risk of onward transmission.

Communicable diseases intelligence (2018)2026 Mar 24

Increasing rates of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Shigella have been detected worldwide. This retrospective review of shigellosis notifications in Southeast Queensland found that XDR Shigella accounted for 48% of notifications. Antimicrobial treatment should be reserved for individuals with severe disease, immunocompromise or high risk of onward transmission.

#5

Genome-wide analysis exploring mechanisms used by Shigella sonnei to survive long-term nutrient starvation.

mSystems2026 Mar 16

Shigella is a major cause of severe diarrhea, with Shigella flexneri and Shigella sonnei accounting for over 90% of infections. Progressive economic growth worldwide correlates with the replacement of S. flexneri by S. sonnei as the dominant cause of shigellosis. The basis of the epidemiological shift remains unclear, but it highlights the urgent need for further studies on the increasingly prevalent, but less well-studied, S. sonnei. Here, we investigated whether S. sonnei is better equipped to survive nutrient starvation, a crucial condition for persistence both outside the host and within the colonic lumen. S. sonnei exhibited greater survival under long-term nutrient starvation (LTNS) than S. flexneri, rapidly activating survival mechanisms. We interrogated the genome of S. sonnei using transposon-directed insertion-site sequencing (TraDIS), revealing that metabolic pathways (ATP, nucleotide, and amino acid synthesis) and envelope homeostasis systems (e.g., Tol-Pal complex, Bam complex, peptidoglycan recycling, and RpoE stress response) are conditionally essential for LTNS. TraDIS findings were validated by non-competitive and competitive survival of wild-type and deletion mutant strains. We compared the homology of conditionally essential genes between S. sonnei and S. flexneri to identify genes potentially involved in differential LTNS survival between the species. However, S. sonnei strains in which a single gene was replaced with the S. flexneri allele showed wild-type survival phenotypes. This suggests that the divergent survival of these two species may be more complex than a monogenic difference. Together, these data define the molecular adaptations of starvation resistance in S. sonnei and provide insights into its epidemiological dominance in high-income countries. Understanding why Shigella sonnei has a higher prevalence than Shigella flexneri as a country undergoes economic growth is an important challenge in Shigella research. The investigation of their biological and genetic differences is key to tackling the impact of the disease. We discovered that S. sonnei resists nutrient deprivation better than S. flexneri, suggesting a better adaptation to an extracellular lifestyle and a greater preservation of metabolic capabilities. Using a genome-wide transposon sequencing approach, we uncovered the key pathways behind the survival of S. sonnei facing nutrient starvation, which include ATP, nucleotide, and amino acid synthesis as well as maintenance of cell envelope integrity. Comparative analysis between S. sonnei and S. flexneri did not identify an individual gene responsible for the differing survival and may reflect a multifactorial difference. Our data provide a genome-wide basis for understanding how S. sonnei is adapted to nutrient-deprived settings, which may be advantageous in the gut lumen and for environmental survival, potentially contributing to its dominance in high-income countries.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.165 artigos no totalmostrando 196

2026

Shigellosis: antibiotics should be strictly reserved for severe disease and cases at very high risk of onward transmission.

Communicable diseases intelligence (2018)
2026

Shigella flexneri and Shigella sonnei among children under five in Kenya's urban informal settlement.

Gut pathogens
2026

Genome-wide analysis exploring mechanisms used by Shigella sonnei to survive long-term nutrient starvation.

mSystems
2026

Investigating Autophagy Genes Expression and their Possible Relations with ‎Apoptosis in PBMCs of Patients with Thin Endometrium.

Iranian journal of immunology : IJI
2026

Looking Beyond the Surface: A Case of Shigella Enterocolitis in a Patient Presenting With Weakness and Substance Use.

Cureus
2026

Optimizing Shigella isolation: a multi-site evaluation of laboratory culture methods for Shigella detection, speciation, and serotyping with different transport media and sample types in the Enterics for Global Health study.

Journal of clinical microbiology
2026

Development of a Novel Shigella Quadrivalent Conjugate Vaccine Using Shigella O-Polysaccharide and IpaB Carrier Protein.

Vaccines
2026

Anti-Shigella activity and killing kinetics of compounds from MMV Pathogen and COVID Boxes: Identifying leads against Shigellosis.

Current research in pharmacology and drug discovery
2026

Genetic Exchanges Shape the Evolutionary Diversification Among Shigella phages.

Journal of molecular evolution
2026

Shigella flexneri 1c bacteremia in a child: a case report.

Gut pathogens
2025

Immunogenicity evaluation of altSonflex1-2-3 Shigella vaccine across mice, rats, and rabbits to inform human translational insights.

Frontiers in immunology
2026

Epidemiology of Shigella Species in Cameroon: Systematic Review and Meta-Analysis.

Tropical medicine &amp; international health : TM &amp; IH
2026

The natural history of the emergence of sexually transmissible shigellosis.

Microbial genomics
2025

Cumulative Incidence of Dysentery Among Under-Five Children in Underprivileged Urban Areas of Bhopal: A One-Year Cohort Study.

Indian journal of community medicine : official publication of Indian Association of Preventive &amp; Social Medicine
2026

Emerging Ceftriaxone Resistance in Paediatric Shigella sonnei: A 10-Year Retrospective Study.

Acta paediatrica (Oslo, Norway : 1992)
2026

A public resource of 15 genomically characterized representative strains of Shigella sonnei.

Microbial genomics
2026

Shigella sonnei and Shigella flexneri: Epidemiology supporting development of cross-protective vaccines.

Human vaccines &amp; immunotherapeutics
2026

PLGA-based nanovaccine delivering chimeric IpaD-StxB protein induces robust immune response against Shigella infection.

Journal of immunological methods
2026

Control of the Food-Borne Pathogen, Shigella flexneri 1457 by Using a Plant Polyphenol Naringenin.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
2025

Rise of the Resistance: A Case of Resistant Shigellosis in an Immunocompetent Female Patient.

Cureus
2026

Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis.

Clinical and translational science
2025

Immunoinformatics-based design of a next generation multi-epitope vaccine candidate against Shigella boydii using a hierarchical subtractive proteomics approach.

Scientific reports
2025

Evaluation of the performance and feasibility of RLDT in detecting Shigella in a primary healthcare facility of rural Bangladesh.

medRxiv : the preprint server for health sciences
2025

Lithocholic acid induces T3SS-dependent formation of invasion-competent Shigella flexneri aggregates.

bioRxiv : the preprint server for biology
2025

Evaluation of cross-functional antibody responses elicited by a four-component GMMA Shigella vaccine.

NPJ vaccines
2026

Defining Severe Shigellosis in the Enterics for Global Health Study: A Comparison of Leading Diarrhea Severity Definitions Among Children With Shigella Diarrhea.

The Journal of infectious diseases
2025

Whole genome analysis of Shigella sp. JZ001: a novel strain isolated from diarrheic suckling mice.

Frontiers in veterinary science
2026

Gut commensal Bifidobacterium longum confers resistance to Salmonella Typhimurium and Shigella flexneri in a Caenorhabditis elegans model.

Microbiology spectrum
2025

Asiatic acid, a novel ciprofloxacin adjuvant inhibits Shigella flexneri infection.

Gut microbes
2025

CagA-positive H. pylori may protect against disease of the hands, feet, and mouth.

Gut pathogens
2025

Evaluating the ciprofloxacin potentiation efficacy of repurposed drug flupentixol through efflux pump inhibition of pathogenic bacteria.

Scientific reports
2025

Enhanced data sharing and coordination to ensure Australia can address the threat of extensively drug-resistant Shigella - a case study for consideration by the Australian Centre for Disease Control.

Communicable diseases intelligence (2018)
2025

Evaluating the Adjuvant Therapeutic Effects of Probiotic Strains Lactococcus cremoris and Lacticaseibacillus paracasei on Canine Atopic Dermatitis and Their Impact on the Gut and Skin Microbiome.

Animals : an open access journal from MDPI
2025

Prevalence of Shigellosis among household contacts of index cases in the EFGH catchment area, Dhaka, Bangladesh.

PLoS neglected tropical diseases
2025

Phage Henu12-resistant mutant derives fitness trade-offs in Shigella dysenteriae.

Microbiology spectrum
2025

Genomic and epidemiological characteristics of Shigella boydii in Australia, 1991-2022.

Pathogens and global health
2025

Extended spectrum β-lactamase and integron genes among Shigella flexneri and Shigella sonnei isolated from children with diarrhea in shiraz, Southwest Iran.

BMC pediatrics
2025

The emergence of sexually transmissible Shigella flexneri serotype 1b between 2019 and 2024 in England: a descriptive epidemiological study.

Microbial genomics
2025

Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
2025

Enhanced virulence and stress tolerance are signatures of epidemiologically successful Shigella sonnei.

Nature communications
2025

Is pre-travel advice followed? A study of UK international travellers with gastrointestinal illness and asymptomatic travellers.

Public health
2025

A computational investigation into the role of tRNAs encoded by Shigella phage Sf14.

BMC genomics
2025

Antibodies elicited by altSonflex1-2-3 GMMA vaccine are bactericidal against a panel of drug-resistant Shigella clinical isolates.

Frontiers in immunology
2025

Cross-comparison study of three ELISA methodologies to measure Shigella Sonnei O-antigen serum IgG.

mSphere
2025

Shigellosis in South East Metropolitan Melbourne, 1 January 2022 - 31 March 2023.

Communicable diseases intelligence (2018)
2025

Neutralizing antibodies induced by IpaB and IpaC mRNA vaccines inhibit Shigella flexneri invasion.

Microbiology spectrum
2025

Macrophages orchestrate elimination of Shigella from the intestinal epithelial cell niche via TLR-induced IL-12 and IFN-γ.

Cell host &amp; microbe
2025

Antimicrobial treatment options for extensively drug-resistant (XDR) shigellosis in men who have sex with men.

Sexually transmitted infections
2025

A "Pandemic-Proof" Methodology for Outbreak Detection Adapted From COVID-19's Impact on Notifications of Infectious Diseases in the Netherlands: Surveillance Study.

JMIR public health and surveillance
2025

Characterization of Shigella virulence factor intracellular spread A (IcsA, or VirG) functional epitopes against S. flexneri 2a and S. sonnei invasion and adherence.

Applied and environmental microbiology
2025

Cinnamomum zeylanicum essential oil inactivates Shigella flexneri by inhibiting biofilm formation, disrupting cell membrane integrity, and suppressing virulence gene expression.

Microbial pathogenesis
2025

An O-Specific Polysaccharide Shigella flexneri 3a Conjugate Vaccine is Immunogenic and Protective against Virulent Keratoconjunctival Challenge in Guinea Pigs.

The American journal of tropical medicine and hygiene
2025

Analyzing Shigella in Wuhan: Serotypes, Antimicrobial Resistance, and Public Health Implications.

Infection and drug resistance
2025

High pathogenic potential of Shigella flexneri strains descending from a common ancestor isolated over 34 years in Brazil.

Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
2025

A multifunctional anti-O-Antigen human monoclonal antibody protects against Shigella sonnei infection in vivo.

Proceedings of the National Academy of Sciences of the United States of America
2025

Impact of the COVID-19 pandemic on five food- and waterborne diseases in six European countries, 2016-21.

European journal of public health
2025

An in-silico-designed multiepitope vaccine candidate can efficiently protect mice against pathogenic species of Shigella.

Journal of immunological methods
2025

Escherichia coli is implicated in the development and manifestation of host susceptibility to the roundworm Trichostrongylus colubriformis infections in sheep.

Veterinary research
2025

Epidemiologic and Genomic Investigation of Sexually Transmitted Shigella sonnei, England.

Emerging infectious diseases
2025

Inhibiting multidrug resistant Shigella flexneri using comparative genomics guided In vitro and In silico screening.

Journal of ethnopharmacology
2025

The fusion subunit vaccine L-DBF protects aged mice against heterologous lethal Shigella challenge after prior exposure.

Frontiers in immunology
2025

Draft genome sequence of a multidrug-resistant Escherichia coli O13/O129:H11 isolate from imported beef in Saudi Arabia.

Microbiology resource announcements
2025

Accelerated electrochemical antibiotic susceptibility testing using disposable electrodes and Resazurin.

Journal of pharmaceutical and biomedical analysis
2025

Shigellosis: an update on the disease and analysis of human cases in the Czech Republic, 2018-2023.

Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne
2025

High Rates of Bacteremia and Fluoroquinolone Resistance During an Outbreak of Shigellosis Among People Experiencing Homelessness and Opioid Use Disorder in Philadelphia, Pennsylvania.

Open forum infectious diseases
2025

Shigella Mutant with Truncated O-Antigen as an Enteric Multi-Pathogen Vaccine Platform.

Vaccines
2025

An Outbreak of Multidrug-Resistant Shigella flexneri Serotype 2a Among People Experiencing Homelessness in Vancouver.

Tropical medicine and infectious disease
2025

Shigella flexneri Bacteremia in an Immunocompetent Woman With Socioeconomic Risk Factors: A Case Report.

Cureus
2025

Multidrug-resistant Shigella flexneri outbreak affecting humans and non-human primates in New Mexico, USA.

Nature communications
2025

Host PIK3C3 promotes Shigella flexneri spread from cell to cell through vacuole formation.

PLoS pathogens
2025

Gut Microbiota Combined With Metabolomics to Reveal the Mechanism of Tang Wang Ming Mu Granule in the Treatment of Diabetic Retinopathy in Mice.

Biomedical chromatography : BMC
2025

Shigella flexneri Outbreak at a Rehabilitation Center: First Report from Saudi Arabia.

Healthcare (Basel, Switzerland)
2025

Spatial visualization provides insight into immune modulation by an L-DBF vaccine formulation against Shigella.

Frontiers in immunology
2025

Assessment of seasonal variations in antibiotic resistance genes and microbial communities in sewage treatment plants for public health monitoring.

Environmental pollution (Barking, Essex : 1987)
2025

DNAzyme-based colorimetric biosensor for rapid detection of Shigella flexneri.

Scientific reports
2025

Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella.

mSphere
2024

Insights from Shigella bacteriophage genomes analysis.

Bioinformation
2025

Evaluation of extended-spectrum β-lactamase producing bacteria in feces of shelter dogs as a biomarker for altered gut microbial taxa and functional profiles.

Frontiers in microbiology
2025

Development of a Novel mRNA Vaccine Against Shigella Pathotypes Causing Widespread Shigellosis Endemic: An In-Silico Immunoinformatic Approach.

Bioinformatics and biology insights
2025

Epidemiology of Shigella species and serotypes in children: a retrospective substudy of the MAL-ED observational birth cohort study.

The Lancet. Microbe
2025

Dynamics of the gut microbiome in subjects challenged with Shigella sonnei 53G in a controlled human infection model.

mSphere
2025

Epidemiology of Burkholderia pseudomallei, Streptococcus suis, Salmonella spp., Shigella spp. and Vibrio spp. infections in 111 hospitals in Thailand, 2022.

PLOS global public health
2025

Genetic characterization of extensively drug-resistant blaCTX-M-27Shigella sonnei clusters among men who have sex with men in a region of northern Spain.

International journal of antimicrobial agents
2025

Silent escalation: The journey of Shigella from gut to blood.

Indian journal of medical microbiology
2025

Tebipenem pivoxil as an alternative to ceftriaxone for clinically non-responding children with shigellosis: a randomised non-inferiority trial protocol.

BMJ open
2025

A case of intercurrent shigellosis and rectal gonorrhea in an acutely unwell febrile returned traveler.

Therapeutic advances in infectious disease
2025

Discovering promising drug candidates for Parkinson's disease: integrating miRNA and DEG analysis with molecular dynamics and MMPBSA.

Journal of computer-aided molecular design
2025

Shigellosis in an Urban Slum in Kenya: Risk Factors and Antimicrobial Resistance.

Open forum infectious diseases
2025

The rise in domestic shigellosis and the genomic characteristics of Shigella clones linked to men who have sex with men in Taiwan, 2015‒2022.

Microbiology spectrum
2025

Shigella sonnei and Shigella flexneri infection in Caenorhabditis elegans led to species-specific regulatory responses in the host and pathogen.

Microbial genomics
2025

Safety, Tolerability, and Immunogenicity of the InvaplexAR-DetoxShigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial.

Vaccines
2025

Modification-specific Proteomic Analysis Reveals Cysteine S-Palmitoylation Involved in Esophageal Cancer Cell Radiation.

ACS omega
2025

Molecular epidemiology of extended-spectrum beta-lactamases and carbapenemases-producing Shigella in Africa: a systematic review and meta-analysis.

BMC infectious diseases
2024

Pharmacokinetics of tebipenem pivoxil used in children suffering from shigellosis: a pilot study in Bangladesh.

Scientific reports
2024

Synergistic efficacy of phage Henu10 with antibiotics against Shigella dysenteriae with insight into phage resistance and fitness trade-offs.

Frontiers in cellular and infection microbiology
2024

Sexually transmitted shigellosis.

Acta dermatovenerologica Alpina, Pannonica, et Adriatica
2025

Shared mechanisms of enhanced plasmid maintenance and antibiotic tolerance mediated by the VapBC toxin:antitoxin system.

mBio
2025

A newly developed oral infection mouse model of shigellosis for immunogenicity and protective efficacy studies of a candidate vaccine.

Infection and immunity
2024

A fractional order model for the transmission dynamics of shigellosis.

Heliyon
2024

High prevalence of CTX-M-15 producing Shigella spp. isolated from patients with gastroenteritis in Northeast Iran.

Acta microbiologica et immunologica Hungarica
2025

Resistome phylodynamics of multidrug-resistant Shigella isolated from diarrheal patients.

Microbiology spectrum
2025

Genomic Epidemiology of Fluoroquinolone-Resistant Strains of Shigella sonnei and Shigella flexneri in the Iberian Peninsula From 2015 to 2022.

The Journal of infectious diseases
2024

Unveiling the Antibacterial Efficacy of a Benzonitrile Small Molecule, IITR00210, in Shigella Infection.

ACS infectious diseases
2025

Increased Severity of Multidrug-Resistant Shigella sonnei Infections in People Experiencing Homelessness.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
2024

Genome and antibiotic resistance characteristics of Shigella clinical isolates in Fujian Province, Southeast China, 2005-2019.

Microbial genomics
2024

Immunization of BALB/c Mice against Shigella sonnei Using a Multiepitope Protein Vaccine through Intranasal and Subcutaneous Administration.

Iranian journal of allergy, asthma, and immunology
2025

Using demographics of patients to inform treatment of shigellosis in England.

The Lancet. Microbe
2024

Addressing Public Health Risks: Strategies to Combat Infectious Diseases After the August 2024 Floods in Bangladesh.

Journal of preventive medicine and public health = Yebang Uihakhoe chi
2024

Whole genome sequencing and antimicrobial resistance among clinical isolates of Shigella sonnei in Addis Ababa, Ethiopia.

PloS one
2024

Impact of an intranasal L-DBF vaccine on the gut microbiota in young and elderly mice.

Gut microbes
2025

"Molecular Characterization of Extended Spectrum Beta-Lactamase Resistance in Pediatric Shigella Isolates in Egypt".

Biochemical genetics
2024

SPATEs promote the survival of Shigella to the plasma complement system upon local hemorrhage and bacteremia.

Proceedings of the National Academy of Sciences of the United States of America
2024

Prevalence of Shigella species and antimicrobial resistance patterns in Africa: systematic review and meta-analysis.

BMC infectious diseases
2024

Evaluation of a Quadrivalent Shigella flexneri Serotype 2a, 3a, 6, and Shigella sonnei O-Specific Polysaccharide and IpaB MAPS Vaccine.

Vaccines
2024

High-Throughput Luminescence-Based Serum Bactericidal Assay Optimization and Characterization to Assess Human Sera Functionality Against Multiple Shigella flexneri Serotypes.

International journal of molecular sciences
2024

Outer membrane protein C is a protective and unique vaccine antigen against Shigella flexneri 3a.

Scientific reports
2025

Epidemiology and antimicrobial resistance rates for Shigella species in a resource-rich setting.

Pathology
2024

[Phage therapy: where do we stand?].

La Revue du praticien
2024

[Risk of acquiring antibiotic-resistant bacteria and travel].

La Revue du praticien
2024

Impact of non-pharmaceutical interventions during the COVID-19 pandemic on pathogens transmitted via food in the Netherlands.

Epidemiology and infection
2024

An RPA-Based CRISPR/Cas12a Assay in Combination with a Lateral Flow Assay for the Rapid Detection of Shigella flexneri in Food Samples.

Foods (Basel, Switzerland)
2024

Trends in shigellosis notifications in England, January 2016 to March 2023.

Epidemiology and infection
2024

Limited O-specific polysaccharide (OSP)-specific functional antibody responses in young children with Shigella infection in Bangladesh.

bioRxiv : the preprint server for biology
2024

A multi-epitope protein vaccine encapsulated in alginate nanoparticles as a candidate vaccine against Shigella sonnei.

Scientific reports
2024

Safety and Tolerability of ShigActive™, a Shigella spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial.

Antibiotics (Basel, Switzerland)
2024

A rhesus macaque intragastric challenge model for evaluating the safety, immunogenicity, and efficacy of live-attenuated Shigella dysenteriae 1 vaccine candidates.

Frontiers in microbiology
2024

Characterization of azithromycin-resistant Shigella flexneri serotype 2a isolates using whole genome sequencing in Ontario from 2016 to 2018.

Microbiology spectrum
2024

Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.

Vaccine
2024

The Impact of Non-Dysentery Shigella Infection on the Growth and Health of Children over Time (INSIGHT)-A Prospective Case-Control Study Protocol.

Microorganisms
2024

Impact of eugenol on biofilm development in Shigella flexneri 1457: a plant terpenoid based-approach to inhibit food-borne pathogen.

Archives of microbiology
2024

Multidrug-Resistant Shigellosis as a Sexually Transmitted Infection in Advanced HIV: A Case Report.

Cureus
2024

Determinants of immune responses predictive of protection against shigellosis in an endemic zone: a systems analysis of antibody profiles and function.

The Lancet. Microbe
2024

The re-emergence of sexually transmissible multidrug resistant Shigella flexneri 3a, England, United Kingdom.

npj antimicrobials and resistance
2024

Adaptation of a fluoroquinolone-sensitive Shigella sonnei to norfloxacin exposure.

Royal Society open science
2024

Twenty-five years of sentinel laboratory-based surveillance of shigellosis in a high-income country endemic for the disease, Israel, 1998 to 2022.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
2024

Mapping the functional B-cell epitopes of Shigella invasion plasmid antigen D (IpaD).

Applied and environmental microbiology
2024

Evaluation of the prophylactic effect of egg yolk antibody (IgY) produced against the recombinant protein containing IpaD, IpaB, StxB, and VirG proteins from Shigella.

Molecular immunology
2024

Multidrug-resistant Shigella flexneri outbreak associated with a high-mortality spillover event into nonhuman primates.

Research square
2024

Supporting health systems and environment in the Democratic Republic of Congo: A call for action.

Health science reports
2025

First report of Shigella sonnei carrying a blaCTX-M-15 sexually transmitted among men who have sex with men.

Infection
2024

Reported Incidence of Infections Caused by Pathogens Transmitted Commonly Through Food: Impact of Increased Use of Culture-Independent Diagnostic Tests - Foodborne Diseases Active Surveillance Network, 1996-2023.

MMWR. Morbidity and mortality weekly report
2024

Communicable diseases in Ukraine during the period of 2018-2023: Impact of the COVID-19 pandemic and war.

Travel medicine and infectious disease
2024

Vaccination with a Protective Ipa Protein-Containing Nanoemulsion Differentially Alters the Transcriptomic Profiles of Young and Elderly Mice following Shigella Infection.

Vaccines
2024

Enteric Infection-Associated Reactive Arthritis: A Systematic Review and Meta-Analysis.

Journal of clinical medicine
2024

Enhancing insights into diseases through horizontal gene transfer event detection from gut microbiome.

Nucleic acids research
2024

Prospective Spatiotemporal Cluster Detection Using SaTScan: Tutorial for Designing and Fine-Tuning a System to Detect Reportable Communicable Disease Outbreaks.

JMIR public health and surveillance
2024

A Qualitative Evaluation of the Acceptability of Shigellosis Prevention Recommendations Among Gay, Bisexual, and Other Men Who Have Sex With Men.

Sexually transmitted diseases
2024

Unlocking the potential of Extensin Signal peptide and Elastin-like polypeptide tag fused to Shigella dysenteriae's IpaDSTxB to improve protein expression and purification in Nicotiana tabacum and Medicagosativa.

Protein expression and purification
2024

Emergence of lineage III of Shigella sonnei ST152 belonging to a high-risk clone harboring the blaCTX-M-15 gene in Peru.

Revista Argentina de microbiologia
2024

Cinnamaldehyde inhibits the NLRP3 inflammasome by preserving mitochondrial integrity and augmenting autophagy in Shigella sonnei-infected macrophages.

Journal of inflammation (London, England)
2024

Identification and analysis of immunoreactive proteins of Shigella flexneri in human sera and stool specimens.

PeerJ
2024

Designing a multi-epitope vaccine against Shigella dysenteriae using immuno-informatics approach.

Frontiers in genetics
2024

Identification of therapeutic drug target of Shigella Flexneri serotype X through subtractive genomic approach and in-silico screening based on drug repurposing.

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
2024

Polyoxometalate-Polymer Directed Macromolecular Architectonics of Silver Nanoparticles as Effective Antimicrobials.

Chemistry, an Asian journal
2024

Investigation of the vaccine potential of an in silico designed FepA peptide vaccine against Shigella flexneri in mice model.

Vaccine: X
2024

Overcoming Microbial Inhibition of S. Sonnei Through the Exploitation of Genomically Predicted Antibiotic Resistance Profiles for the Development of Food Enrichment Media.

Journal of food protection
2025

Extended-Spectrum β-Lactamase Shigella sonnei Cluster Among Men Who Have Sex With Men in Chicago, Illinois, July-October 2022.

The Journal of infectious diseases
2024

Strain-specific Recovery of S. sonnei from Artificially Contaminated Baby Carrots: Enhancing Food-safety Investigations with a Customized Shigella Detection Method Based on Genomically predicted Antibiotic Resistance Traits.

Journal of food protection
2024

Metagenomic dissection of the intestinal microbiome in the giant river prawn Macrobrachium rosenbergii infected with Decapod iridescent virus 1.

Fish &amp; shellfish immunology
2024

Prevalence, associated factors and antimicrobial susceptibility patterns of Salmonella and Shigella species among diarrheic under five children in Sultan Sheik Hassan Yabere referral Hospital, Jigjiga, Eastern Ethiopia.

BMC pediatrics
2024

Rapid diagnostic tests and loop-mediated isothermal amplification method for the detection of Shigella species: A systematic review and meta-analysis.

Journal of infection and public health
2024

Development of a visual Adhesion/Invasion Inhibition Assay to assess the functionality of Shigella-specific antibodies.

Frontiers in immunology
2024

Testing S. sonnei GMMA with and without Aluminium Salt-Based Adjuvants in Animal Models.

Pharmaceutics
2024

Shigella Vaccines: The Continuing Unmet Challenge.

International journal of molecular sciences
2024

Risk Factors of Seizure in Childhood Shigellosis.

Iranian journal of child neurology
2024

Prolonged Ileus Due to Underlying Shigella Infection After Bilateral Open Inguinal Hernia Repair.

Cureus
2024

IgG Serum Antibodies to Shigella sonnei Lipopolysaccharide Are Inversely Associated with the Incidence of Culture-Proven S. sonnei Shigellosis in Israeli Children and Adolescents.

Vaccines
2024

Exploring Natural Immune Responses to Shigella Exposure Using Multiplex Bead Assays on Dried Blood Spots in High-Burden Countries: Protocol From a Multisite Diarrhea Surveillance Study.

Open forum infectious diseases
2024

The Enterics for Global Health (EFGH) Shigella Surveillance Study in Kenya.

Open forum infectious diseases
2024

The Enterics for Global Health (EFGH) Shigella Surveillance Study in Peru.

Open forum infectious diseases
2024

Microbiological Methods Used in the Enterics for Global Health Shigella Surveillance Study.

Open forum infectious diseases
2024

Multidrug-resistant conjugative plasmid carrying mphA confers increased antimicrobial resistance in Shigella.

Scientific reports
2024

Modulating the antibacterial effect of the existing antibiotics along with repurposing drug metformin.

Archives of microbiology
2024

The epidemiological profile of incidence and mortality from epidemics in complex humanitarian emergencies from 1990 to 2022 - A scoping review.

Tropical medicine &amp; international health : TM &amp; IH
2024

Epidemiological analysis and prevention strategies in response to a shigellosis cluster outbreak: a retrospective case series in an alternative school in the Republic of Korea, 2023.

Osong public health and research perspectives
2024

Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine.

NPJ vaccines
2024

Risk Factors of Developing Postinfectious Irritable Bowel Syndrome in Shigellosis Patients, 5 Years After Hospitalization During the Outbreak.

Open forum infectious diseases
2024

Recent advances in modelling Shigella infection.

Trends in microbiology
2024

Bioinformatics Analysis and Experimental Validation of Mitochondrial Autophagy Genes in Knee Osteoarthritis.

International journal of general medicine
2024

Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.

Frontiers in immunology
2024

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology.

Journal of visualized experiments : JoVE
2024

Collecting a Sexual History During Shigellosis Case Investigations: Nationwide Practices and an Assessment of Data Quality.

Foodborne pathogens and disease
2024

Molecular Signature of Monocytes Shaped by the Shigella sonnei 1790-Generalized Modules for Membrane Antigens Vaccine.

International journal of molecular sciences
2024

PEtN-Modified O-Antigen Enhances Shigella Pathogenesis by Promoting Epithelial Cell Invasion and Inhibiting Complement Binding.

ACS infectious diseases
2024

MULTISPECIES SHIGELLA FLEXNERI OUTBREAK IN A ZOOLOGICAL COLLECTION COINCIDING WITH A CLUSTER IN THE LOCAL HUMAN POPULATION.

Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
2023

Identification of Renal Transplantation Rejection Biomarkers in Blood Using the Systems Biology Approach.

Iranian biomedical journal
2023

Shigella as a Cause of Diarrhea Hospitalization in Children Under Five: Evaluation by Conventional and Molecular Methods.

Cureus
2024

Experimental and pharmacoinformatic approaches unveil the neuropharmacological and analgesic potential of chloroform fraction of Roktoshirinchi (Achyranthes ferruginea Roxb.).

Journal of ethnopharmacology
2024

Expression and purification of TolC as a recombinant protein vaccine against Shigella flexneri and evaluation of immunogenic response in mice.

Microbial pathogenesis
2023

Comparison of the Intestinal Bacterial Communities between Captive and Semi-Free-Range Red-Crowned Cranes (Grus japonensis) before Reintroduction in Zhalong National Nature Reserve, China.

Animals : an open access journal from MDPI
2023

Characterization of genotypes and antimicrobial resistance profiles of clinical isolates of Shigella from patients in the southern region of Iran.

European journal of medical research
2023

Characterizations of novel broad-spectrum lytic bacteriophages Sfin-2 and Sfin-6 infecting MDR Shigella spp. with their application on raw chicken to reduce the Shigella load.

Frontiers in microbiology
2023

Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta).

PloS one
2023

Healthcare providers' knowledge and clinical practice surrounding shigellosis - DocStyles Survey, 2020.

BMC primary care
2023

Crystallographic Fragment Screening on the Shigella Type III Secretion System Chaperone IpgC.

ACS omega
2023

Refining Immunogenicity through Intradermal Delivery of Outer Membrane Vesicles against Shigella flexneri in Mice.

International journal of molecular sciences
Ver todos os 1.165 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Shigelose.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Shigelose e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

A shigelose é provocada pela infecção por bactérias Gram-negativas pertencentes ao gênero *Shigella*. As espécies descritas como causadoras são *S. dysenteriae*, *S. flexneri*, *S. boydii* e *S. sonnei*.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

9 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:810
    Orphanet
  2. GARD:4818
    GARD (NIH)
  3. Q327298
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Shigelose. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/shigelose

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Shigelose
Compêndio · Raras BR

Shigelose

ORPHA:810 · MONDO:0019345
Prevalência
Unknown
Herança
Not applicable
CID-10
A03.8 · Outras shigueloses
CID-11
Ensaios
9 ativos
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0013371
EuropePMC
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Rara